Lenalidomid Olainfarm (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4^CRBN E3 ubiquitin ligase complex. This binding changes the complex’s substrate specificity, leading to degradation of transcription factors that promote tumor growth. The result is reduced angiogenesis, enhanced immune response against cancer cells, and direct anti‑tumor activity.

The dosage of Lenalidomid Olainfarm is determined by the prescribing physician based on the specific indication, disease stage, patient weight, renal function, and other clinical factors. Patients should follow the exact dosing regimen provided by their healthcare professional and not adjust the dose on their own.

Lenalidomid Olainfarm is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential must use effective contraception. The safety of the drug during breastfeeding has not been established, so nursing mothers should avoid its use.

To request Lenalidomid Olainfarm, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lenalidomid Olainfarm (lenalidomide) belongs to the immunomodulatory imide drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It provides oral administration, anti‑angiogenic and immune‑enhancing effects, and is often used in combination regimens. Choice of therapy depends on disease characteristics, prior treatments, and patient tolerance.

Lenalidomid Olainfarm tablets should be stored at ambient temperature below 25 °C. Keep them in the original packaging, protect from moisture and direct light, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

The medication is supplied as oral tablets. Patients swallow the tablet whole with water, usually once daily or as directed by their physician. It can be taken with or without food, but consistency with meals may help reduce gastrointestinal discomfort.

Serious risks include venous thromboembolism, severe neutropenia or thrombocytopenia that can lead to infection or bleeding, liver toxicity, and the potential for secondary primary malignancies. Patients should be monitored regularly for blood counts, liver function, and signs of clotting events.

Lenalidomid Olainfarm should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled active infections or severe hepatic impairment without close supervision. Clinicians must evaluate each patient’s medical history before initiating therapy.